Aktis Oncology Statistics
Total Valuation
Aktis Oncology has a market cap or net worth of $1.18 billion. The enterprise value is $942.14 million.
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Aktis Oncology has 52.52 million shares outstanding. The number of shares has increased by 53.35% in one year.
| Current Share Class | 50.65M |
| Shares Outstanding | 52.52M |
| Shares Change (YoY) | +53.35% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.11% |
| Owned by Institutions (%) | 0.17% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.20 |
| Forward PS | n/a |
| PB Ratio | 5.85 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 169.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.27, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.27 |
| Quick Ratio | 9.19 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.50% and return on invested capital (ROIC) is -18.92%.
| Return on Equity (ROE) | -26.50% |
| Return on Assets (ROA) | -14.80% |
| Return on Invested Capital (ROIC) | -18.92% |
| Return on Capital Employed (ROCE) | -28.93% |
| Revenue Per Employee | $73,158 |
| Profits Per Employee | -$798,013 |
| Employee Count | 76 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 1.69 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 989,409 |
Short Selling Information
The latest short interest is 7.25 million, so 13.80% of the outstanding shares have been sold short.
| Short Interest | 7.25M |
| Short Previous Month | 3.59M |
| Short % of Shares Out | 13.80% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.54 |
Income Statement
In the last 12 months, Aktis Oncology had revenue of $5.56 million and -$60.65 million in losses. Loss per share was -$76.44.
| Revenue | 5.56M |
| Gross Profit | -58.00M |
| Operating Income | -72.94M |
| Pretax Income | -60.65M |
| Net Income | -60.65M |
| EBITDA | -70.87M |
| EBIT | -72.94M |
| Loss Per Share | -$76.44 |
Full Income StatementBalance Sheet
The company has $246.22 million in cash and $11.87 million in debt, with a net cash position of $234.36 million or $4.46 per share.
| Cash & Cash Equivalents | 246.22M |
| Total Debt | 11.87M |
| Net Cash | 234.36M |
| Net Cash Per Share | $4.46 |
| Equity (Book Value) | 201.02M |
| Book Value Per Share | -162.43 |
| Working Capital | 222.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$61.69 million and capital expenditures -$7.66 million, giving a free cash flow of -$69.34 million.
| Operating Cash Flow | -61.69M |
| Capital Expenditures | -7.66M |
| Free Cash Flow | -69.34M |
| FCF Per Share | -$1.32 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,311.94% |
| Pretax Margin | -1,090.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
